Fundies.
English

AZIYO BIOLOGICS, INC.

EDGAR
AZYO Quarterly report (10-Q) · filed 2026-08-14

35 filing records in this dataset, filed from 2020-09-14 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist
Cash and cash equivalents
19.9 million Unit_Standard_USD_qixKwxX5k0-o-Afd5t2rdA Source
Exact value

19896000 Unit_Standard_USD_qixKwxX5k0-o-Afd5t2rdA

Long-term debt including current maturities
26.1 million Unit_Standard_USD_THuRHapv60-SBEn6Z7-RIg Source
Exact value

26103000 Unit_Standard_USD_THuRHapv60-SBEn6Z7-RIg

Shares outstanding
649 thousand Unit12 Source
Exact value

648679 Unit12

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 2 of 11 periods available· newest 2025-12-31
  • Net income: 2 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 2 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 2 of 11 periods available· newest 2025-12-31
  • Total assets: Multiple units; comparison withheld· newest 2025-12-31
  • Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Current assets: Multiple units; comparison withheld· newest 2025-12-31
  • Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
  • Long-term debt including current maturities: Multiple units; comparison withheld· newest 2024-12-31
  • Shares outstanding: 1 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    +Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 107.33 million

    Prior period

    −Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 53.95 million

    –

    Current period

    Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 53.38 million

    –

    Exact inputs and evidence

    53380000 − -53949000 = 107329000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

    -53949000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    53380000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    −Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 22.14 million

    Prior period

    −Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 22.66 million

    –

    Current period

    −Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 44.8 million

    –

    Exact inputs and evidence

    -44800000 − -22657000 = -22143000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

    -22657000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -44800000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    +186.9%

    Prior period

    Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 654,000

    –

    Current period

    Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 1.88 million

    –

    Exact inputs and evidence

    1876000 − 654000 = 1222000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

    654000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    1876000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2024 2024-01-01 – 2024-12-31
−Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 53.95 million
Exact value

Exact value: -53949000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

2024-01-01 – 2024-12-31: -53949000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 22.66 million
Exact value

Exact value: -22657000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

2024-01-01 – 2024-12-31: -22657000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 654,000
Exact value

Exact value: 654000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

2024-01-01 – 2024-12-31: 654000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 23.31 million
Calculation and evidence

-22657000 − 654000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

Exact free cash flow: -23311000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 53.38 million
Exact value

Exact value: 53380000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

2025-01-01 – 2025-12-31: 53380000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 44.8 million
Exact value

Exact value: -44800000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

2025-01-01 – 2025-12-31: -44800000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 1.88 million
Exact value

Exact value: 1876000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

2025-01-01 – 2025-12-31: 1876000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA 46.68 million
Calculation and evidence

-44800000 − 1876000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

Exact free cash flow: -46676000 Unit_Standard_USD_Qg1-F4zRCUyCTPK392pBAA

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

35 filings · 2,963 latest values · 2,963 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001708527, 1708527, AZYO, ELUT, edgar:1708527

Also known as AZIYO BIOLOGICS, INC., AZIYO BIOLOGICS, INC., Aziyo Biologics, Inc., Aziyo Biologics, Inc., ELUTIA INC., Elutia Inc., Elutia Inc.